<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051384</url>
  </required_header>
  <id_info>
    <org_study_id>20-AOIP-05</org_study_id>
    <secondary_id>2021-A01289-32</secondary_id>
    <nct_id>NCT05051384</nct_id>
  </id_info>
  <brief_title>Superb Microvascular Intraocular Tumor Imaging Study (SMITIS)</brief_title>
  <acronym>SMITIS</acronym>
  <official_title>Using the Superb Microvascular Imaging Method in the Diagnosis of Intraocular Tumors (SMITIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis and monitoring of intraocular tumors are based on multimodal imaging in&#xD;
      addition to the clinical examination (ultra-widefield retinal imaging, echography,&#xD;
      angiography). Nevertheless, it may be difficult in cases of retinal hemorrhage, small tumor&#xD;
      size or atypical presentation. The study of microvascular flow (Superb Microvascular Imaging,&#xD;
      SMI) of intraocular tumors could improve the confidence of differential diagnosis when&#xD;
      evaluating these suspicious lesions, or even determine whether a lesion is benign or&#xD;
      malignant by describing the vascularization of the lesion.&#xD;
&#xD;
      The investigators propose to study the microvascular flow patterns of intraocular tumors&#xD;
      prior to proton therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ultrasound equipment available in ophthalmology does not have Doppler technology and does&#xD;
      not allow the study of the vascularization and microvascularization of intraocular lesions.&#xD;
      The interest in the system used in this study is to import SMI into ophthalmology to study&#xD;
      tumor microvascularization. The study of tumor vascularization can help in the differential&#xD;
      diagnosis and follow-up of tumors, and therefore can impact the management of patients with&#xD;
      tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 17, 2021</start_date>
  <completion_date type="Anticipated">September 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative description of the intratumoral microvascular flow</measure>
    <time_frame>Visite 2 - two weeks after Day 0</time_frame>
    <description>Number of visible feeding pedicles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Qualitative description of the intratumoral microvascular flow</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of visible feeding pedicles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantification of microvascular flow for each tumor</measure>
    <time_frame>Visite 2 2weeks after Day 0</time_frame>
    <description>Presence or absence of arteriovenous shunts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantification of microvascular flow for each tumor</measure>
    <time_frame>month 6</time_frame>
    <description>Presence or absence of arteriovenous shunts</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ocular Tumor</condition>
  <arm_group>
    <arm_group_label>Intraocular tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New sonographic software technique on ultrasonography to detect low-vascular flow inside intraocular tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Doppler technology</intervention_name>
    <description>The study of tumor vascularization can help in the differential diagnosis and follow-up of tumors, and therefore can impact the management of patients with tumors</description>
    <arm_group_label>Intraocular tumor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Intraocular tumor not previously treated with proton therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe active ocular, periocular or intraocular inflammation&#xD;
&#xD;
          -  Intraocular pressure &gt; 30 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion CAUSERET</last_name>
    <phone>0492034702</phone>
    <email>causeret.m@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CAUSERET Marion</name>
      <address>
        <city>Nice</city>
        <state>Chu de Nice</state>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>CAUSERET Marion</last_name>
      <phone>0492034702</phone>
      <email>causeret.m@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>NAON-ESTEVE sacha, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

